Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLSD NASDAQ:CVKD NASDAQ:MIRA NASDAQ:XTLB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLSDClearside Biomedical$0.32-8.6%$7.16$0.29▼$1.65$27.45M2.11601,433 shs1.36 million shsCVKDCadrenal Therapeutics$13.15-2.6%$12.12$8.74▼$22.90$27.63M0.9523,942 shs18,990 shsMIRAMIRA Pharmaceuticals$1.45-12.7%$1.50$0.73▼$2.56$31.66M1.75190,460 shs1.12 million shsXTLBXTL Biopharmaceuticals$1.32+16.4%$3.99$0.86▼$3.05$7.60M1.087,278 shsN/A10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLSDClearside Biomedical-93.33%-93.84%-95.26%-97.34%-98.37%CVKDCadrenal Therapeutics0.00%-0.68%+1.78%-5.12%+58.05%MIRAMIRA Pharmaceuticals0.00%+3.57%-1.36%+19.83%+2.84%XTLBXTL Biopharmaceuticals0.00%+14.85%-9.00%+2.73%-50.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLSDClearside Biomedical$0.32-8.6%$7.16$0.29▼$1.65$27.45M2.11601,433 shs1.36 million shsCVKDCadrenal Therapeutics$13.15-2.6%$12.12$8.74▼$22.90$27.63M0.9523,942 shs18,990 shsMIRAMIRA Pharmaceuticals$1.45-12.7%$1.50$0.73▼$2.56$31.66M1.75190,460 shs1.12 million shsXTLBXTL Biopharmaceuticals$1.32+16.4%$3.99$0.86▼$3.05$7.60M1.087,278 shsN/A10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLSDClearside Biomedical-93.33%-93.84%-95.26%-97.34%-98.37%CVKDCadrenal Therapeutics0.00%-0.68%+1.78%-5.12%+58.05%MIRAMIRA Pharmaceuticals0.00%+3.57%-1.36%+19.83%+2.84%XTLBXTL Biopharmaceuticals0.00%+14.85%-9.00%+2.73%-50.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLSDClearside Biomedical 2.17Hold$63.0019,618.31% UpsideCVKDCadrenal Therapeutics 3.00Buy$32.00143.35% UpsideMIRAMIRA Pharmaceuticals 3.50Strong Buy$17.001,072.41% UpsideXTLBXTL Biopharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest XTLB, MIRA, CVKD, and CLSD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/18/2025CLSDClearside BiomedicalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$75.007/18/2025CLSDClearside BiomedicalChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral7/18/2025CLSDClearside BiomedicalStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$30.007/17/2025CLSDClearside BiomedicalJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/17/2025CLSDClearside BiomedicalNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeModerate Buy ➝ Hold$45.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLSDClearside Biomedical$4.17M6.02N/AN/A($0.51) per share-0.63CVKDCadrenal TherapeuticsN/AN/AN/AN/A$4.17 per shareN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/A$0.13 per shareN/AXTLBXTL Biopharmaceuticals$450K15.93N/AN/A$1.00 per share1.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLSDClearside Biomedical-$34.35M-$0.37N/AN/AN/A-665.19%N/A-124.15%11/11/2025 (Estimated)CVKDCadrenal Therapeutics-$10.65M-$8.88N/AN/AN/AN/A-265.37%-196.38%11/6/2025 (Estimated)MIRAMIRA Pharmaceuticals-$7.85M-$0.49N/AN/AN/AN/A-406.70%-328.44%11/11/2025 (Estimated)XTLBXTL Biopharmaceuticals-$1.03MN/A0.00∞N/AN/AN/AN/AN/ALatest XTLB, MIRA, CVKD, and CLSD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025MIRAMIRA Pharmaceuticals-$0.11-$0.09+$0.02-$0.09N/AN/A8/11/2025Q2 2025CVKDCadrenal Therapeutics-$1.60-$1.87-$0.27-$1.87N/AN/A8/8/2025Q2 2025CLSDClearside Biomedical-$1.80-$0.90+$0.90-$0.06$0.50 million$0.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLSDClearside BiomedicalN/AN/AN/AN/AN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/AN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/AN/AXTLBXTL BiopharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLSDClearside BiomedicalN/A3.873.87CVKDCadrenal TherapeuticsN/A3.553.55MIRAMIRA PharmaceuticalsN/A2.802.80XTLBXTL BiopharmaceuticalsN/A0.610.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLSDClearside Biomedical18.75%CVKDCadrenal Therapeutics7.92%MIRAMIRA Pharmaceuticals35.16%XTLBXTL Biopharmaceuticals4.40%Insider OwnershipCompanyInsider OwnershipCLSDClearside Biomedical6.70%CVKDCadrenal Therapeutics26.09%MIRAMIRA Pharmaceuticals6.65%XTLBXTL Biopharmaceuticals29.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLSDClearside Biomedical3078.51 million73.25 millionOptionableCVKDCadrenal Therapeutics42.05 million1.51 millionNot OptionableMIRAMIRA Pharmaceuticals219.07 million17.80 millionNot OptionableXTLBXTL BiopharmaceuticalsN/A5.45 million3.87 millionNot OptionableXTLB, MIRA, CVKD, and CLSD HeadlinesRecent News About These CompaniesXTL Biopharmaceuticals Approves Key Resolutions at Shareholder MeetingJuly 28, 2025 | tipranks.comXTL Biopharmaceuticals Stock (NASDAQ:XTLB), Insider Trading ActivityJuly 8, 2025 | benzinga.comXTL Biopharmaceuticals Ltd. (XTLB) - Yahoo FinanceJune 30, 2025 | uk.finance.yahoo.comXTL Biopharmaceuticals names Noam Band as CEOApril 9, 2025 | uk.investing.comXTL Biopharmaceuticals Ltd.: XTL Names Mr. Noam Band as its New Chief Executive OfficerApril 8, 2025 | finanznachrichten.deXTL Biopharmaceuticals Appoints Noam Band as CEOApril 7, 2025 | tipranks.comXTL Names Mr. Noam Band as its New Chief Executive OfficerApril 7, 2025 | globenewswire.comXTL Biopharmaceuticals Reports Financial Results Amid Regional UnrestDecember 30, 2024 | tipranks.comXTL Biopharmaceuticals Expands Portfolio with Social Proxy Acquisition Amidst Regional ChallengesDecember 30, 2024 | tipranks.comXTL Biopharmaceuticals (NASDAQ:XTLB) Stock, Short Interest ReportNovember 5, 2024 | benzinga.comXTL Biopharmaceuticals Ltd (XTLB)September 5, 2024 | investing.comXTL Biopharmaceuticals Ltd XTLBAugust 22, 2024 | morningstar.comMXTL Biopharmaceuticals acquires AI firm Social ProxyAugust 16, 2024 | uk.investing.comXTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 MillionAugust 14, 2024 | globenewswire.comXTL Biopharmaceuticals Ltd. (XTLB.TA)July 22, 2024 | finance.yahoo.comXTL Entered Definitive Agreement to Acquire The Social ProxyJune 5, 2024 | globenewswire.comXTL Biopharmaceuticals Ltd. ADRApril 26, 2024 | wsj.comU.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.03%March 20, 2024 | msn.comUS Stocks Edge Lower Ahead Of Fed's Decision; General Mills Earnings Top ViewsMarch 20, 2024 | msn.comDow Surges 350 Points; Fed Holds Rates SteadyMarch 20, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXTLB, MIRA, CVKD, and CLSD Company DescriptionsClearside Biomedical NASDAQ:CLSD$0.32 -0.03 (-8.61%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.33 +0.01 (+3.60%) As of 09/12/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.Cadrenal Therapeutics NASDAQ:CVKD$13.15 -0.35 (-2.59%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$13.55 +0.40 (+3.04%) As of 09/12/2025 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.MIRA Pharmaceuticals NASDAQ:MIRA$1.45 -0.21 (-12.65%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.48 +0.03 (+2.07%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.XTL Biopharmaceuticals NASDAQ:XTLBXTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
